[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse XRN1

Summary
SymbolXRN1
Name5'-3' exoribonuclease 1
Aliases strand-exchange protein 1 homolog
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Note=Discrete foci at the inner surface of the cell membrane.
Domain PF03159 XRN 5'-3' exonuclease N-terminus
Function

Major 5'-3' exoribonuclease involved in mRNA decay. Required for the 5'-3'-processing of the G4 tetraplex-containing DNA and RNA substrates. The kinetic of hydrolysis is faster for G4 RNA tetraplex than for G4 DNA tetraplex and monomeric RNA tetraplex. Binds to RNA and DNA (By similarity). Plays a role in replication-dependent histone mRNA degradation. May act as a tumor suppressor protein in osteogenic sarcoma (OGS).

> Gene Ontology
 
Biological Process GO:0000956 nuclear-transcribed mRNA catabolic process
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0008334 histone mRNA metabolic process
GO:0010608 posttranscriptional regulation of gene expression
GO:0016072 rRNA metabolic process
GO:0016075 rRNA catabolic process
GO:0019439 aromatic compound catabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0034661 ncRNA catabolic process
GO:0043487 regulation of RNA stability
GO:0043488 regulation of mRNA stability
GO:0044270 cellular nitrogen compound catabolic process
GO:0046700 heterocycle catabolic process
GO:0071025 RNA surveillance
GO:0071027 nuclear RNA surveillance
GO:0071028 nuclear mRNA surveillance
GO:0071044 histone mRNA catabolic process
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:1901361 organic cyclic compound catabolic process
Molecular Function GO:0004518 nuclease activity
GO:0004527 exonuclease activity
Cellular Component GO:0045111 intermediate filament cytoskeleton
> KEGG and Reactome Pathway
 
KEGG hsa03008 Ribosome biogenesis in eukaryotes
hsa03018 RNA degradation
Reactome R-HSA-450385: Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
R-HSA-429914: Deadenylation-dependent mRNA decay
R-HSA-74160: Gene Expression
R-HSA-450531: Regulation of mRNA stability by proteins that bind AU-rich elements
R-HSA-450513: Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
R-HSA-430039: mRNA decay by 5' to 3' exoribonuclease
Summary
SymbolXRN1
Name5'-3' exoribonuclease 1
Aliases strand-exchange protein 1 homolog
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between XRN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolXRN1
Name5'-3' exoribonuclease 1
Aliases strand-exchange protein 1 homolog
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of XRN1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 5.22; FDR: 0.003 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolXRN1
Name5'-3' exoribonuclease 1
Aliases strand-exchange protein 1 homolog
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of XRN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0860.77
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1690.889
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0320.968
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1230.742
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0520.983
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3490.912
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2170.589
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3810.824
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0310.987
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9720.308
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.990.147
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1070.0198
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of XRN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolXRN1
Name5'-3' exoribonuclease 1
Aliases strand-exchange protein 1 homolog
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of XRN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolXRN1
Name5'-3' exoribonuclease 1
Aliases strand-exchange protein 1 homolog
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of XRN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by XRN1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolXRN1
Name5'-3' exoribonuclease 1
Aliases strand-exchange protein 1 homolog
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of XRN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolXRN1
Name5'-3' exoribonuclease 1
Aliases strand-exchange protein 1 homolog
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of XRN1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolXRN1
Name5'-3' exoribonuclease 1
Aliases strand-exchange protein 1 homolog
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between XRN1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolXRN1
Name5'-3' exoribonuclease 1
Aliases strand-exchange protein 1 homolog
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting XRN1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.